Allovir Stock Today
| ALVR Stock | USD 9.65 0.53 5.81% |
PerformanceVery Weak
| Odds Of DistressBelow Average
|
Allovir is selling at 9.65 as of the 16th of March 2025; that is 5.81 percent increase since the beginning of the trading day. The stock's lowest day price was 9.46. Allovir has about a 39 percent probability of financial distress in the next few years of operation and has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 16th of December 2024 and ending today, the 16th of March 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 30th of July 2020 | Category Healthcare | Classification Health Care |
Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell therapies to prevent and treat devastating viral-associated diseases. Allovir, Inc. was founded in 2013 and is based in Waltham, Massachusetts. The company has 115.36 M outstanding shares of which 64.61 K shares are presently shorted by private and institutional investors with about 26.44 trading days to cover. More on Allovir
Moving together with Allovir Stock
Moving against Allovir Stock
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Allovir Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsAllovir can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Allovir's financial leverage. It provides some insight into what part of Allovir's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||
Allovir (ALVR) is traded on NASDAQ Exchange in USA. It is located in 1100 Winter Street, Waltham, MA, United States, 02451 and employs 8 people. Allovir is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 85.25 M. Allovir conducts business under Biotechnology sector and is part of Health Care industry. The entity has 115.36 M outstanding shares of which 64.61 K shares are presently shorted by private and institutional investors with about 26.44 trading days to cover.
Allovir currently holds about 172.67 M in cash with (67.7 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.91.
Check Allovir Probability Of Bankruptcy
Ownership AllocationAllovir holds a total of 115.36 Million outstanding shares. Allovir retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Allovir Ownership Details
Allovir Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Marshall Wace Asset Management Ltd | 2024-12-31 | 324.7 K | |
| Fmr Inc | 2024-09-30 | 310.6 K | |
| Two Sigma Investments Llc | 2024-09-30 | 295.2 K | |
| State Street Corp | 2024-09-30 | 222.4 K | |
| Northern Trust Corp | 2024-09-30 | 158.4 K | |
| Citadel Advisors Llc | 2024-09-30 | 84.2 K | |
| Jane Street Group Llc | 2024-09-30 | 83.4 K | |
| Samsara Biocapital, Llc | 2024-09-30 | 82.3 K | |
| Dimensional Fund Advisors, Inc. | 2024-09-30 | 69.8 K | |
| Ecor1 Capital, Llc | 2024-09-30 | 11.3 M | |
| Octagon Capital Advisors Lp | 2024-12-31 | 11.2 M |
Allovir Historical Income Statement
Allovir Stock Against Markets
Allovir Corporate Management
| Sonia Choi | Senior Relations | Profile | |
| Agustin MD | Advisor | Profile | |
| Dana MBA | VP Operations | Profile | |
| Ann Leen | Chief Officer | Profile | |
| Cintia PharmD | Chief Officer | Profile | |
| David Hallal | Executive Board | Profile | |
| Jeroen Beek | Consultant | Profile |
Already Invested in Allovir?
The danger of trading Allovir is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Allovir is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Allovir. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Allovir is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Additional Tools for Allovir Stock Analysis
When running Allovir's price analysis, check to measure Allovir's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Allovir is operating at the current time. Most of Allovir's value examination focuses on studying past and present price action to predict the probability of Allovir's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Allovir's price. Additionally, you may evaluate how the addition of Allovir to your portfolios can decrease your overall portfolio volatility.